Exact Sciences ‘applauds’ passage of MCED legislation

Exact Sciences (EXAS) celebrates the passage of federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection , or MCED, tests. “By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging technology for millions of Medicare beneficiaries,” the company stated. “It’s a historic day in the fight against cancer. We are deeply grateful to lawmakers, especially Representatives Terri Sewell and Jodey Arrington, patient advocates, and all those who fought tirelessly for this groundbreaking legislation. Most importantly, we are thrilled for the countless individuals whose lives will be impacted by these tests, potentially giving them more opportunities to celebrate birthdays, anniversaries, and precious moments with their loved ones,” said Kevin Conroy, chairman and CEO of Exact Sciences.